From the Food and Drug Administration.
Schwetz
B A
BA
Office of the Commissioner of Food and Drugs, Rockville, MD 20857, USA.
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000284:Administration, Oral; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002400:Cathartics / Q000008:administration & dosage / Q000009:adverse effects*; D017147:Defibrillators, Implantable; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D018670:Monitoring, Ambulatory; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010138:Pacemaker, Artificial; D019999:Pharmaceutical Solutions; D010710:Phosphates / Q000008:administration & dosage / Q000009:adverse effects*; D000068698:Tenofovir; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load; D014883:Water-Electrolyte Imbalance / Q000139:chemically induced
D019380:Anti-HIV Agents; D002400:Cathartics; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D019999:Pharmaceutical Solutions; D010710:Phosphates; D000068698:Tenofovir; D000225:Adenine; C018279:sodium phosphate